REQUEST FORM FOR BENZNIDAZOLE & NIFURTIMOX

CONSIGNMENT DELIVERY DETAILS

Request date:
Name of consignee:
E-mail address:
Telephone number:

Name of institution:
Postal address (with postal or zip code):
Telephone number:

EPIDEMIOLOGICAL AND CLINICAL INFORMATION OF PATIENTS TO BE TREATED

Patient number	Medicine requested	No. of bottles or boxes needed[a,b]	Age (years)	Body weight (kg)	Likely transmission route	Likely place of infection	Place of birth	Disease phase (acute/chronic/ reactivation due to immunosuppression)
Other relevant information (optional):								

[a] **benznidazole** A box of benznidazole produced by the Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE Benznidazole) contains 100 tablets of 100 mg (slotted) or 12.5 mg each. A box produced by Laboratorio ELEA (Abarax) contains 100 tablets (slotted twice) of 100 mg or 50 mg each. The recommended dosage is 5 mg/kg daily in adults (up to 10 mg/kg daily in children) for 60 days.

[b] **nifurtimox** A box of nifurtimox produced by Bayer (Lampit) contains 100 tablets of 120 mg each. The recommended dosage is 8–10 mg/kg in adults (up to 15 mg/kg daily in children) for 60 days.

Recommendations

- **Treatment** should not be initiated without previous assessment of the possibility of completing the entire treatment and of detecting at an early stage any adverse reaction during the course of treatment.
- **Adverse events during treatment** Any serious adverse events or reactions that occur during treatment with benznidazole and nifurtimox should be reported to their National Pharmacovigilance Centre (NPC). Countries without an NPC should send their reports to the national drug regulatory authority (NDRA); the NPC or the NDRA should submit reports, in due course, to the WHO global database at the Uppsala monitoring centre.

Versions-Nummer: **1.0**
version number:

Erstveröffentlichung: **10/2022**
Initial release:

Nächste Überprüfung geplant: **09/2027**
Review planned: